Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

NCT02773355 · Completed

Last updated 2026-05-28

This clinical trial is testing how often serious and non-serious side effects, including pancreatitis, occur in Mexican adults with obesity who are taking Saxenda®.

Status Completed The study has finished.

Type Observational

Participants 27 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-05 · est. completion 2022-02

Where 14 sites · Mexico

What this study is testing ClinicalTrials.gov NCT02773355 ↗

Description as written by the study sponsor.

This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in Mexican patients.

Treatments tested

liraglutide 3.0 mg Drug

Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.

Main thing measured	Frequency of pancreatitis
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02773355 ↗